PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.
Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein markedly overexpressed on prostate cancer cells, enabling a single molecular target to support both positron emission tomography (PET) imaging and targeted radionuclide therapy. Over the past decade, PSMA-PET/CT has been incorporated into...